NCT03539536 2025-11-05Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerAbbViePhase 2 Active not recruiting270 enrolled 1 FDA
NCT02414139 2024-03-20Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)NovartisPhase 2 Completed373 enrolled 34 charts 3 FDA